# Genor Biopharma Co., Ltd. clinical trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Genor Biopharma Co., Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genor Biopharma Co., Ltd.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/genor-biopharma-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 18, 2025 | NCT06934616 | A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors | Genor Biopharma Co., Ltd. | Phase 1 | Not yet recruiting | Solid Tumor Cancer | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06934616) |
| May 16, 2023 | NCT05860582 | A Study of \[14C\]GB491 in Male Healthy Subjects | Genor Biopharma Co., Ltd. | Phase 1 | Completed | Breast Cancer, Nonsmall Cell Lung Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05860582) |
| May 9, 2023 | NCT05851014 | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | Genor Biopharma Co., Ltd. | Phase 3 | Recruiting | Breast Cancer | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05851014) |
| April 20, 2022 | NCT05337657 | A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Advanced Breast Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05337657) |
| April 18, 2022 | NCT05332574 | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | Genor Biopharma Co., Ltd. | Phase 1/2 | Unknown | NSCLC, Other Solid Tumors | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05332574) |
| September 23, 2021 | NCT05054751 | GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer | Genor Biopharma Co., Ltd. | Phase 3 | Completed | Locally Advanced or Metastatic Breast Cancer | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05054751) |
| June 11, 2021 | NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | Genor Biopharma Co., Ltd. | Phase 1/2 | Unknown | B Cell NHL, CLL | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04923048) |
| May 27, 2021 | NCT04905667 | Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ® | Genor Biopharma Co., Ltd. | Phase 1 | Completed | Breast Cancer | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04905667) |
| November 27, 2019 | NCT04179513 | A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Rheumatoid Arthritis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04179513) |
| November 26, 2019 | NCT04178850 | Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection | Genor Biopharma Co., Ltd. | Phase 3 | Unknown | Rheumatoid Arthritis | 568 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04178850) |
| November 26, 2019 | NCT04178070 | Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Rheumatoid Arthritis | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04178070) |
| November 26, 2019 | NCT04178057 | Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles. | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Brain Tumor | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04178057) |
| November 26, 2019 | NCT04178044 | Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Bone Tumor | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04178044) |
| November 22, 2019 | NCT04175171 | Clinical Trial of Comparative Study of GB221 Pharmacokinetics | Genor Biopharma Co., Ltd. | Phase 1 | Completed | Metastatic Breast Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04175171) |
| November 22, 2019 | NCT04175158 | Clinical Trial in Chinese Healthy Volunteers of GB222 | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Non-small Cell Lung Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04175158) |
| November 20, 2019 | NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | Genor Biopharma Co., Ltd. | Phase 1/2 | Unknown | HER2-positive Breast Cancer | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04170595) |
| November 15, 2019 | NCT04164615 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection | Genor Biopharma Co., Ltd. | Phase 3 | Unknown | HER-2-positive Advanced Breast Cancer | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04164615) |
| June 6, 2019 | NCT03977090 | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Metastatic Colorectal Cancer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03977090) |
| June 6, 2019 | NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Metastatic Non-small Cell Lung Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03976856) |
| January 18, 2019 | NCT03808857 | A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive | Genor Biopharma Co., Ltd. | Phase 2 | Unknown | Cervical Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03808857) |
| August 21, 2018 | NCT03639181 | Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) | Genor Biopharma Co., Ltd. | Phase 2 | Unknown | B-cell Non-Hodgkin's Lymphoma | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03639181) |
| August 9, 2018 | NCT03623581 | Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) | Genor Biopharma Co., Ltd. | Phase 2 | Unknown | Alveolar Soft Part Sarcoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03623581) |
| April 18, 2018 | NCT03502629 | Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) | Genor Biopharma Co., Ltd. | Phase 2 | Unknown | Peripheral T Cell Lymphoma | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03502629) |
| December 14, 2017 | NCT03374007 | Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma | Genor Biopharma Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma, Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03374007) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 18 |
| Completed | 4 |
| Recruiting | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Arthritis, Rheumatoid | 3 |
| Lymphoma, B-Cell | 1 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Bone Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Lymphoma | 1 |
| Hodgkin Disease | 1 |
| Brain Neoplasms | 1 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 1 |
| Uterine Cervical Neoplasms | 1 |
| Sarcoma, Alveolar Soft Part | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
- [Employment law firms in the United States](https://specstream.ai/data/businesses/employment-law-firms/united-states)
- [Coffee shops in the United States](https://specstream.ai/data/businesses/coffee-shops/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
